BlossomHill Therapeutics, Inc. (BLSM) is a San Diego-based, clinical-stage biopharmaceutical company that designs small-molecule oncology drugs. Its lead asset, BH-30643, is an OMNI-EGFR inhibitor in the Phase 1/2 SOLARA trial for EGFR-mutant non-small cell lung cancer; BH-30236, a CLK inhibitor, is in Phase 1 for relapsed AML and higher-risk MDS; and BH-501284 is a preclinical pan-KRAS candidate. The company went public in August 2026 at $16 per share and carries a market value of roughly $480 million on about 31.8 million shares.
Shares closed the November 17 session at $15.18, a gain of 11.21% from the prior close of $13.65. The direction was decisively higher, with the stock opening at $13.69 and grinding to a $15.37 high before settling near the top of the range. No verified news catalyst was found for the move.
No verified news or fundamental catalyst found explains today's advance. The company's most recent substantive disclosures — the November 9 announcement of FDA alignment on a 50 mg twice-daily Phase 2 dose and pivotal SOLARA-2 design, and the November 12 third-quarter report — were both published days before this session and had already been absorbed by the market. Shares sold off after those releases, so today's action is not a delayed reaction to them.
The most plausible read is technical. BLSM had fallen 15% in four sessions and opened Tuesday near $13.09, close to the November 5 low of $11.02. A sharp bounce from that zone, on volume roughly 1.5 times the recent average, is consistent with short-covering and dip-buying in a stock with a modest free float and a habit of violent swings. Over the past 60 sessions the average absolute daily move has been about 4.8%, and seven sessions produced moves of 11.2% or more — including a 14.9% jump, an 18.4% rally, and a 13.3% decline. Today's move was roughly 2.3 times the typical daily range, sizable but not statistically rare for this name.
Participation was clearly elevated: turnover of roughly 323,000 shares compared with a 10-day average near 215,000, though still below the heaviest sessions of September and early October. There was no corresponding move in large-cap biotechnology benchmarks or in any identified peer with comparable EGFR or KRAS exposure, which reinforces that the buying was idiosyncratic rather than sector-driven.
Technically, the session carried the stock back above its 20-day average near $14.42, a level it had lost during the prior week's slide, and put distance between the price and the November low. Resistance remains in the $16.10 to $16.40 band, where the stock stalled twice in November. The move did not reclaim the 50-day trend, which still slopes lower.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event lands at 15 out of 100.
The news component is weak: no verified development was published on the session, and the recent FDA alignment and quarterly report were already public and priced in. The price component is also moderate, not extreme. Today's 11.21% gain was about 2.3 times the stock's typical daily move, but moves of that size or larger have occurred seven times in the last 60 sessions. With only one weak component in play, the combined result stays low.
Attention now turns to the December ASH Annual Meeting, where updated BH-30236 data in relapsed AML and higher-risk MDS are scheduled for presentation — the next scheduled fundamental catalyst. Investors will also watch for confirmation that the first patient has been dosed in the registrational SOLARA-2 cohort, the event the company has flagged as the gateway to a potential accelerated approval filing.
The balance sheet remains the key risk buffer and the key constraint: roughly $224.9 million in cash against no product revenue and a quarterly net loss in the low-$20-million range, implying a runway measured in years but dependent on trial scope. A 180-day lock-up tied to the August IPO expires in early February 2027, introducing potential supply risk. Sell-side coverage established after the offering is uniformly positive, and any change in that stance — or a quiet stretch of news flow — could leave the stock to trade on technicals alone.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots spanning thousands of tickers. Bots differ widely by strategy logic, holding period, performance metrics, and the symbols they trade, so the featured lineup shifts as market conditions change. Reviewing which robots are trending can help traders see how systematic strategies are positioned right now. Visit the page to explore the current leaders and compare their approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology